Rhode Island Hospital

60 Degrees Pharmaceuticals, Inc. is conducting a double-blind, placebo-controlled trial in collaboration with Brigham and Women’s Hospital to evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial aims to assess safety and efficacy, with endpoints including time to symptom resolution and molecular cure. Recruitment of 24-33 patients is planned for summer 2025, with an interim analysis expected in early 2026.

60 Degrees Pharmaceuticals expands tafenoquine clinical trial for babesiosis to Brigham and Women's Hospital. The double-blind, placebo-controlled study evaluates tafenoquine with standard treatment for hospitalized babesiosis patients. The trial aims to recruit 24-33 patients in summer 2025, with interim analysis expected in early 2026. Main endpoints are time to sustained clinical resolution and molecular cure. Recent case studies indicate high cure rates in immunosuppressed patients with relapsing babesiosis. The company estimates the accessible market through 2035 could exceed 400,000 patients.

Sarah Frost, new president and chief of operations at Hasbro Children's Hospital and Rhode Island Hospital, discusses workforce retention and reimbursement challenges. She aims to expand primary care access and improve patient experience. Lifespan is restructuring, including layoffs and a partnership with Brown University, and is adding St. Anne's and Morton Hospitals to its network.